One Small Startup's Quest For Funding Gets Creative
By Camille Mojica Rey, Contributing Writer
Follow Me On Twitter
It’s no wonder small biopharma companies are acquired by their larger counterparts only after clinical trials show a novel drug’s potential for success. R&D costs are expensive, accounting for about half of the average cost to develop and gain marketing approval for a new drug. That leaves those small startups with the job of raising massive amounts of money just to stay afloat during the clinical trials process — and hoping for an acquisition exit.
As CEO of Ensysce Biosciences, a semi-virtual company with three employees, Lynn Kirkpatrick, Ph.D., knows all about the funding struggles of a small company. “Every small biotech understands that it costs so much and takes so much infrastructure to commercialize your own product that M&A is inevitably at the top of the list of options for getting a product to market,” she says. “Seeking funding is a 24/7 job. As soon as we get money, I’m out looking for more.”
Get unlimited access to:
Enter your credentials below to log in. Not yet a member of Life Science Leader? Subscribe today.